Hanning Tang

the First Affiliated Hospital with Nanjing Medical University, China (People's Republic)

Poster(s):

• 1429 - Orelabrutinib, fludarabine, cyclophosphamide and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated phase II trial (cwcll-001 trial)